术后大分割挽救放疗中每日自适应放疗的早期临床与剂量学结果
这项前瞻性观察研究评估了AI辅助每日自适应放疗在前列腺癌术后局部区域复发患者中行中度大分割挽救放疗的剂量学指标与早期毒性。 interim分析纳入42例患者共840次治疗分次,自适应计划较预定计划显著改善直肠V52.8Gy、直肠每分次Dmean、前列腺床PTV95%、盆腔PTV95%及PTV107%和肠管Dmax,2级胃肠道毒性和泌尿生殖毒性分别为4.8%和9.5%。
要点
- 自适应计划较预定计划显著降低直肠V52.8Gy和每分次Dmean,并改善靶区覆盖。
- 2级胃肠道毒性总体4.8%,2级泌尿生殖毒性总体9.5%。
- 单因素分析中仅盆腔纳入与腹泻发生相关(p=0.002)。
核心结论
- 初步数据显示急性毒性极小,需更长随访确认并评估晚期毒性。
研究设计与样本
- 前瞻性观察研究(4181CESC,NCT05884632),纳入前列腺癌前列腺切除术后PSMA PET-CT确认M0的局部区域复发患者。
- eligible患者年龄不超过80岁,接受每日20次自适应大分割挽救放疗,宏观复发剂量至59 Gy,仅生化复发55 Gy,必要时盆腔照射45 Gy。
- 使用Ethos系统生成预定计划(基于每日合成CT重算剂量)和自适应计划(基于每日解剖重新优化),由用户选择治疗计划。
- 本次为中期分析,报告前42例患者共840次治疗分次的DVH指标和毒性结果。
主要发现
- 16例(37.2%)仅生化复发,27例(62.8%)宏观复发。
- 自适应计划较预定计划显著改善直肠V52.8Gy(16.9%对12.8%;p≤0.0001)。
- 自适应计划较预定计划显著降低直肠每分次Dmean(1.54 Gy/次对1.42 Gy/次;p≤0.0001)。
- 自适应计划较预定计划显著改善前列腺床PTV95%(92.1%对98.5%;p≤0.0001)、盆腔PTV95%(p<0.0001)、盆腔PTV107%(p<0.0001)和肠管Dmax(p<0.0001)。
- 前列腺床PTV107%、膀胱Dmean和膀胱V40.8Gy在两组间无差异;2级胃肠道毒性总体4.8%,2级泌尿生殖毒性总体9.5%;单因素分析中仅盆腔纳入与腹泻发生相关(p=0.002),治疗剂量与毒性无差异。
关键数值与推荐
- 宏观复发处方剂量至59 Gy/20次,仅生化复发55 Gy/20次,必要时盆腔45 Gy。
- 自适应计划较预定计划:直肠V52.8Gy 16.9%对12.8%(p≤0.0001),直肠每分次Dmean 1.54 Gy对1.42 Gy(p≤0.0001),前列腺床PTV95% 92.1%对98.5%(p≤0.0001)。
- 2级胃肠道毒性总体4.8%,2级泌尿生殖毒性总体9.5%;盆腔纳入与腹泻发生相关(p=0.002)。
临床怎么用
- 在前列腺癌术后大分割挽救放疗中,可考虑使用AI辅助每日自适应放疗以改善直肠剂量和靶区覆盖。
- 纳入盆腔照射时需关注腹泻风险。
- 早期毒性较低,但仍需长期随访评估晚期毒性。
局限性
- 本文为中期分析,样本量有限(42例患者、840次治疗分次),随访时间短,晚期毒性尚未评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To evaluate dose-volume histogram metrics and preliminary toxicity of prostate cancer (PC) patients affected by postoperative locoregional relapse treated with moderately hypofractionated salvage radiotherapy (sRT) using AI-assisted daily adaptive RT. METHODS: This is a prospective observational study (4181CESC, NCT05884632) on adaptive hypofractionated sRT in PC. Eligible patients (up to 80 years old, post-prostatectomy, PSMA PET-CT confirmed M0) received 20 daily fractions up to 59 Gy for macroscopic relapse and 55 Gy for biochemical-only relapse. When indicated, pelvis was included with a dose of 45 Gy. The treatment was administered using Ethos™ system which generates two plans: scheduled and adapted. The scheduled plan includes a dose recalculation on daily synthetic CT (generated from daily CBCT). The adapted plan consists on a reoptimization based on the daily anatomy. The user then select the preferred one for treatment. This is an interim analysis reporting on DVH metrics (scheduled versus adapted plan) and toxicity outcome. RESULTS: The results of the first 840 treatment fractions in 42 patients are reported. Sixteen (37.2%) had biochemical relapse only, while 27 (62.8%) had macroscopic relapse. We reported a significant improvement between scheduled and adapted plan for rectum V52.8Gy (16.9% versus 12.8%); p ≤0.0001), rectum Dmean per fraction (1.54Gy/fraction versus 1.42 Gy/fraction; p ≤0.0001), prostate bed PTV95%, (92.1% versus 98.5%; p ≤0.0001), pelvis PTV95% (<0.0001), pelvis PTV107% (<0.0001), and bowel Dmax (<0.0001). There was no difference for prostate bed PTV107%, bladder Dmean, and bladder V40.8Gy. Grade 2 GI toxicity (overall) was 4.8%. Grade 2 GU toxicity (overall) was 9.5% of cases. In the univariate analysis, the only factor associated with diarrhea onset was the inclusion of the pelvis (p = 0.002). There was no difference between treatment dose and toxicity. CONCLUSION: Preliminary data seems to show minimal acute toxicity. A longer follow up is needed to confirm these data and evaluate late toxicity.
引用
- Nicosia L, Borgese RF, Bianchi N, et al. Daily adaptive radiotherapy in postoperative hypofractionated salvage radiothERapy for prostate cancer patients (DART-PHASER): Early clinical and dosimetric results. Clin Transl Radiat Oncol. 2026. PMID: 42564987. doi:10.1016/j.ctro.2026.101230
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。